MX2009014246A - Antigeno de vacuna con la capacidad de inducir anticuerpo de neutralizacion y reaccion cruzada contra virus de papiloma humano del tipo de alto riesgo. - Google Patents

Antigeno de vacuna con la capacidad de inducir anticuerpo de neutralizacion y reaccion cruzada contra virus de papiloma humano del tipo de alto riesgo.

Info

Publication number
MX2009014246A
MX2009014246A MX2009014246A MX2009014246A MX2009014246A MX 2009014246 A MX2009014246 A MX 2009014246A MX 2009014246 A MX2009014246 A MX 2009014246A MX 2009014246 A MX2009014246 A MX 2009014246A MX 2009014246 A MX2009014246 A MX 2009014246A
Authority
MX
Mexico
Prior art keywords
epitope
human papillomavirus
reacting
risk
neutralizing antibody
Prior art date
Application number
MX2009014246A
Other languages
English (en)
Inventor
Tadahito Kanda
Kazunari Kondo
Original Assignee
Japan Health Science Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Health Science Found filed Critical Japan Health Science Found
Publication of MX2009014246A publication Critical patent/MX2009014246A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)

Abstract

Se describe un antígeno de vacuna con la capacidad de inducir un anticuerpo de reactividad cruzada y de neutralización dirigido contra el virus de papiloma humano del tipo de alto riesgo. En forma específica se describen: una proteína quimérica que comprende el epítope L2 de un virus de papiloma humano (HPV) tipo 16 insertada en una región de lazo de la proteína LI de virus de papiloma humano tipo 16; y un cápsido el cual es un agregado de la proteína quimérica. La región de lazo a la cual se insertará el epítope L2 se localiza entre un residuo de aminoácido en la posición 430 y un residuo de aminoácido en la posición 433. El epítope L2 ha sido una secuencia de aminoácido representada por cualesquiera de las siguientes fórmulas: LYKTCKQAGTCPPDIIPKVEG (epítope L2 18-32); GGLGIGTGSGTGGRTGYIPL (epítope L2 56-75); y DPVGPLDPSIVSLVEESSFI (epítope L2 96-115).
MX2009014246A 2007-06-26 2008-06-25 Antigeno de vacuna con la capacidad de inducir anticuerpo de neutralizacion y reaccion cruzada contra virus de papiloma humano del tipo de alto riesgo. MX2009014246A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007167154 2007-06-26
PCT/JP2008/061569 WO2009001867A1 (ja) 2007-06-26 2008-06-25 高リスク群ヒトパピローマウイルスに対する交差性中和抗体を誘導するワクチン抗原

Publications (1)

Publication Number Publication Date
MX2009014246A true MX2009014246A (es) 2010-03-31

Family

ID=40185679

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009014246A MX2009014246A (es) 2007-06-26 2008-06-25 Antigeno de vacuna con la capacidad de inducir anticuerpo de neutralizacion y reaccion cruzada contra virus de papiloma humano del tipo de alto riesgo.

Country Status (14)

Country Link
US (1) US9023364B2 (es)
EP (1) EP2168977B1 (es)
JP (1) JP5540329B2 (es)
KR (2) KR20150090285A (es)
CN (1) CN101835796A (es)
AU (1) AU2008268014B2 (es)
BR (1) BRPI0813309B8 (es)
CA (1) CA2691745C (es)
ES (1) ES2688474T3 (es)
MX (1) MX2009014246A (es)
MY (1) MY152175A (es)
NZ (1) NZ582271A (es)
RU (1) RU2471807C2 (es)
WO (1) WO2009001867A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2199301A1 (en) 2008-12-19 2010-06-23 DKFZ Deutsches Krebsforschungszentrum Immunogenic polypeptides comprising a scaffold polypeptide and a L2 polypeptide or fragment thereof
DK2416798T3 (en) * 2009-04-10 2018-01-08 Univ Johns Hopkins PAPILLOMAVIRUS-LIKE PARTICLES (VLP) AS WIDE-SPECIFIED VACCINES AGAINST HUMAN PAPILLOMAVIRUS (HPV)
CN102497880A (zh) * 2009-06-25 2012-06-13 葛兰素史密丝克莱恩生物有限公司 新的人乳头状瘤病毒(hpv)蛋白构建体及其在预防hpv疾病中的用途
EP2585477B1 (en) * 2010-06-23 2018-05-30 Deutsches Krebsforschungszentrum Rearranged tt virus molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity
US9279161B2 (en) * 2010-12-27 2016-03-08 Japan Health Sciences Foundation Monoclonal antibody recognizing human papillomavirus (HPV) L2 protein and method for measuring HPV-neutralizing antibody titer using the same
US20150344529A1 (en) * 2012-12-25 2015-12-03 The Chemo-Sero-Therapeutic Research Institute Vaccine for hpv infection and/or hepatitis b comprising hpv/hbs chimeric protein as active ingredient
CN107188966B (zh) * 2016-03-15 2020-03-31 中国医学科学院基础医学研究所 一种乳头瘤病毒嵌合蛋白及其用途
CN114716560B (zh) * 2021-01-04 2024-02-02 中国医学科学院基础医学研究所 一种人乳头瘤病毒18型嵌合蛋白及其用途
CN114716562B (zh) * 2021-01-04 2023-11-10 中国医学科学院基础医学研究所 一种人乳头瘤病毒58型嵌合蛋白及其用途
CN114716561B (zh) * 2021-01-04 2024-03-12 中国医学科学院基础医学研究所 一种人乳头瘤病毒31型嵌合蛋白及其用途
CN115724950B (zh) * 2022-11-15 2023-10-03 怡道生物科技(苏州)有限公司 Hpv6型衣壳蛋白l1单克隆抗体、制备方法及应用
CN116199772B (zh) * 2022-11-16 2023-10-17 怡道生物科技(苏州)有限公司 Hpv31型衣壳蛋白l1单克隆抗体、制备方法及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL183781B1 (pl) * 1994-05-16 2002-07-31 Merck & Co Inc Sposób wytwarzania szczepionki przeciwko ludzkiemu wirusowi brodawczaków
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
RU2229307C1 (ru) * 2002-10-22 2004-05-27 ООО "Фирма"БиоМедИнвест" Композиция рекомбинантных белков, способ получения такой композиции, фармацевтический набор реагентов для иммунотерапии и профилактической вакцинации опухолевых заболеваний аногенитальной сферы, способ иммунотерапии и профилактической вакцинации на его основе
JP4945730B2 (ja) 2004-04-09 2012-06-06 財団法人ヒューマンサイエンス振興財団 粘膜指向性ヒトパピローマウイルス群の感染予防ワクチン抗原
KR20080025171A (ko) 2005-06-21 2008-03-19 메드이뮨 백신즈 인코포레이티드 이종성 프로테아제를 발현시키기 위한 방법 및 조성물
JP4825958B2 (ja) * 2005-08-10 2011-11-30 財団法人ヒューマンサイエンス振興財団 高リスク群ヒトパピローマウイルスの中和抗体を誘導する抗原

Also Published As

Publication number Publication date
JPWO2009001867A1 (ja) 2010-08-26
CN101835796A (zh) 2010-09-15
RU2471807C2 (ru) 2013-01-10
KR20100029216A (ko) 2010-03-16
MY152175A (en) 2014-08-15
US9023364B2 (en) 2015-05-05
CA2691745A1 (en) 2008-12-31
AU2008268014A1 (en) 2008-12-31
KR101624358B1 (ko) 2016-05-26
EP2168977A4 (en) 2013-12-18
EP2168977A1 (en) 2010-03-31
EP2168977B1 (en) 2018-08-08
BRPI0813309B8 (pt) 2021-05-25
WO2009001867A1 (ja) 2008-12-31
ES2688474T3 (es) 2018-11-02
CA2691745C (en) 2017-08-15
BRPI0813309A2 (pt) 2014-12-23
JP5540329B2 (ja) 2014-07-02
RU2009148037A (ru) 2011-06-27
NZ582271A (en) 2012-03-30
US20100183648A1 (en) 2010-07-22
AU2008268014B2 (en) 2013-10-31
KR20150090285A (ko) 2015-08-05
BRPI0813309B1 (pt) 2020-10-06

Similar Documents

Publication Publication Date Title
MX2009014246A (es) Antigeno de vacuna con la capacidad de inducir anticuerpo de neutralizacion y reaccion cruzada contra virus de papiloma humano del tipo de alto riesgo.
MX2011009438A (es) Anticuerpos anti-cd40 y usos de los mismos.
MX337397B (es) Vacunas anti-virales dirigidas a celulas que presentan antigeno.
NZ594985A (en) Anti-bcma (b-cell maturation antigen, cd269, tnfrsf17) antibodies
WO2010104749A8 (en) Antigen presenting cell targeted cancer vaccines
WO2010149752A3 (en) Novel human papillomavirus (hpv) protein constructs and their use in the prevention of hpv disease
MX2008010611A (es) Derivados de 3-desazapurina como moduladores de receptores similares a toll.
WO2008039267A3 (en) Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
MX2011000767A (es) Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos.
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
EP3584251A3 (en) Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines
NZ601793A (en) Methods and compositions for diagnosis and treatment of cancer
MX352338B (es) Anticuerpos neutralizantes del virus de la influenza a y usos de estos.
MX2011007307A (es) Vector de expresion estable contitutivamente alto para preparar vacuna vph y bacteria acido lactica recombinante transformada del mismo modo.
BR112013032723A2 (pt) antígenos amplamente reativos computacionalmente otimizados para influenza h1n1
MY159500A (en) Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
NO20090194L (no) Rekombinant viral vaksine
WO2012027365A3 (en) Targeted multi-epitope dosage forms for induction of an immune response to antigens
MX2013014109A (es) Proteina de fusion que comprende el mutante crm197 no toxico de toxina de difteria.
MX2011008971A (es) Anticuerpos anti-cemx que pueden enlazarse a mlge humana en linfocitos b.
NZ601345A (en) Combination adjuvant formulation
MX2011006846A (es) Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv.
IN2014DN05695A (es)
NZ611168A (en) Monoclonal antibody recognizing human papilloma virus (hpv) l2 protein and method for measuring hpv-neutralizing antibody titer using the same
WO2012149160A3 (en) Viruses modified with unnatural moieties and methods of use thereof

Legal Events

Date Code Title Description
FG Grant or registration